Legend Biotech Corporation (LEGN) News

Form 144 - Report of proposed sale of securities

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Legend Biotech Reports Second Quarter 2023 Results and Recent Highlights

A supplemental Biologics License Application (sBLA) was submitted to the U.S. Food and Drug Administration (FDA) and a Type II Variation...

Legend Biotech to Host Investor Conference Call on Second-Quarter Results

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Report of Proposed Sale of Securities (144)

Form 144 Filer Information UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF...